PYC
data caveat$1.1B26mo
PYC Therapeutics
Biotech · RNA therapeutics
Precision RNA therapeutics for genetic diseases, lead program VP-001 for retinitis pigmentosa
Data HealthTrials5 of 5 active · stale enrollment
Cash data from Dec 2025 4C(5mo old)Figures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$120.7M
Dec 2025 4C
Runway
26moSTABLE
Based on Dec 2025 4C
Market Cap
$1.1B
Burn Rate
$13.8M/qtr
Dec 2025 4C
Shares Outstanding
983M
Pipeline Assets
2
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveOther6 May 2026
PKD - Initiation of Multiple Dose Clinical Trial
PYC Therapeutics has initiated a Phase 1b Multiple Ascending Dose (MAD) clinical trial for PYC-003 in polycystic kidney disease patients, with the first patient dosed. The trial will evaluate safety, tolerability, and efficacy endpoints including urinary PC1 protein levels, total kidney volume, and glomerular filtration rate, with data expected in CY27.
3M Price
PYC.ASX$1.160-20.3% 3M
Low $1.065High $1.455
Pipeline Assets (2)
Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Transactions
4 transactionsLast 90dNet Buy
Buys2
Sells0
Buy Value$200k
warning2 directors bought within 30 days (03-06 – 03-24) — $504k total
Catalysts (7)· 3 upcoming · 4 past
VP-001 Phase 1/2 RP11 further data
UpcomingExpectedarrow_upwardHigh30 June 2026
Expectedarrow_upwardHigh31 Dec 2027
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
2/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High91/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 2 of 2 guided dates· rolling 2yr(limited sample)· of 7 tracked
What drove these scores · rolling 2yr
arrow_drop_up
Stable burn rate — 12% quarterly variation — consistent spend
arrow_drop_up
R&D-focused spend — 97% of opex directed to R&D
Completed catalysts
✓VP-001 EMA — Orphan Drug Designation Granted for RP11 by EMA— The European Medicines Agency (EMA) has granted Orphan Drug Designation to VP-001, PYC Therapeutics' investigational RNA therapy candidate for the rare blinding eye disease Retinitis Pigmentosa type 11. The designation provides benefits including 10 years of European market exclusivity upon approval, scientific advice, and reduced regulatory review fees.
On time
✓PKD - Initiation of Multiple Dose Clinical Trial— PYC Therapeutics has initiated a Phase 1b Multiple Ascending Dose (MAD) clinical trial for PYC-003 in polycystic kidney disease patients, with the first patient dosed. The trial will evaluate safety, tolerability, and efficacy endpoints including urinary PC1 protein levels, total kidney volume, and glomerular filtration rate, with data expected in CY27.
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
↗ SLIPPED
Clinical Trials(8)
5 activeClinicalTrials.gov ↗
Ph1RecruitingEnrollment stale · 429d
PYC-003
Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RandomizedTriple Blind18 Years – 65 Years
Primary endpoint [Part A, B and C] Number of participants experiencing treatment emergent adverse events (AE) as assessed by CTCAE V5.0
ENROL116
no manual snapshots — enter via record_enrollment.py
Ph1/PHASE2RecruitingEnrollment stale · 253d
PYC-001
Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)
OPA1 Gene Mutation · Autosomal Dominant Optic Atrophy · Hereditary Optic Atrophies +1 more
RandomizedOpen Label18 Years+
Primary endpoint [All Cohorts] Number of participants experiencing treatment emergent adverse events
ENROL18
no manual snapshots — enter via record_enrollment.py
Active Not RecruitingOBSERVATIONALEnrollment stale · 1434d
Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
Retinitis Pigmentosa · Eye Diseases, Hereditary · Retinal Dystrophies +2 more
10 Years+
Primary endpoint Change from Baseline in Best Corrected Visual Acuity (BCVA)
ENROL50
no manual snapshots — enter via record_enrollment.py